Cara Therapeutics | CARA - Assets


Cara Therapeutics reported $25.82M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.79B 51.25M Sep/2026
Alterity Therapeutics Limited AUD 37.98M 15.78M Dec/2025
Cara Therapeutics USD 25.82M 6.26M Mar/2026
Cassava Sciences USD 100.06M 3.84M Sep/2026
Chugai Pharma JPY 2.37T 75.59B Sep/2026
Cipla INR 434.34B 9.38B Sep/2026
Clal Biotechnology ILS 158.39M 24.3M Dec/2023
Compugen USD 138.36M 7.5M Jun/2026
CSL USD 37.9B 1.5B Dec/2025
Grifols EUR 23.15B 142.7M Dec/2025
Halozyme Therapeutics USD 3.47B 895.94M Sep/2026
J&J USD 197.42B 3.64B Sep/2026
Neurocrine Biosciences USD 5.63B 268.3M Sep/2026
Pacira USD 34.68B 33.44B Sep/2026
Pfizer USD 204.54B 3.41B Sep/2026
RedHill Biopharma USD 26.27M 929K Jun/2026
Supernus Pharmaceuticals USD 1.4B 30.42M Sep/2026
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025